News | June 02, 2022
Vial to launch oncology CRO, Arati Rao named as First Advisor
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
This product will be manufactured at Lupin’s Nagpur facility in India
The groundbreaking, uniquely robust Robert A. Winn Diversity in Clinical Trials Award Program is on track to train more than 500 individuals from diverse backgrounds by 2027
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
